Glucocorticoids and Glucocorticoid-Induced-Leucine-Zipper (GILZ) in Psoriasis.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2019
Historique:
received: 12 04 2019
accepted: 02 09 2019
entrez: 2 10 2019
pubmed: 2 10 2019
medline: 21 10 2020
Statut: epublish

Résumé

Psoriasis is a prevalent chronic inflammatory human disease initiated by impaired function of immune cells and epidermal keratinocytes, resulting in increased cytokine production and hyperproliferation, leading to skin lesions. Overproduction of Th1- and Th17-cytokines including interferon (IFN)-γ, tumor necrosis factor (TNF)-α, interleukin (IL)-23, IL-17, and IL-22, is a major driver of the disease. Glucocorticoids (GCs) represent the mainstay protocol for treating psoriasis as they modulate epidermal differentiation and are potent anti-inflammatory compounds. The development of safer GC-based therapies is a high priority due to potentially severe adverse effects associated with prolonged GC use. Specific efforts have focused on downstream anti-inflammatory effectors of GC-signaling such as GC-Induced-Leucine-Zipper (GILZ), which suppresses Th17 responses and antagonizes multiple pro-inflammatory signaling pathways involved in psoriasis, including AP-1, NF-κB, STAT3, and ROR-γt. Here we review evidence regarding defective GC signaling, GC receptor (GR) function, and GILZ in psoriasis. We discuss seemingly contradicting data on the loss- and gain-of-function of GILZ in the imiquimod-induced mouse model of psoriasis. We also present potential therapeutic strategies aimed to restore GC-related pathways.

Identifiants

pubmed: 31572404
doi: 10.3389/fimmu.2019.02220
pmc: PMC6753639
doi:

Substances chimiques

Anti-Inflammatory Agents 0
Cytokines 0
Glucocorticoids 0
Receptors, Glucocorticoid 0
TSC22D3 protein, human 0
Transcription Factors 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

2220

Informations de copyright

Copyright © 2019 Sevilla and Pérez.

Références

Front Endocrinol (Lausanne). 2015 Nov 09;6:170
pubmed: 26617572
Front Immunol. 2019 Jan 22;9:3111
pubmed: 30723476
J Immunol. 2014 Jun 15;192(12):5635-42
pubmed: 24808372
F1000Res. 2018 Feb 19;7:205
pubmed: 29527301
Mol Cell Endocrinol. 2015 Sep 5;412:281-9
pubmed: 26001834
J Invest Dermatol. 2017 Aug;137(8):1630-1637
pubmed: 28359725
Nat Rev Mol Cell Biol. 2017 Mar;18(3):159-174
pubmed: 28053348
J Dermatol Sci. 2016 Oct;84(1):11-16
pubmed: 27431412
Mol Endocrinol. 2012 Jun;26(6):1000-13
pubmed: 22556341
J Invest Dermatol. 2016 Dec;136(12):2417-2426
pubmed: 27464843
Physiol Rev. 2013 Jul;93(3):1139-206
pubmed: 23899562
J Invest Dermatol. 2018 Apr;138(4):734-736
pubmed: 29579456
Am J Physiol Endocrinol Metab. 2011 Jul;301(1):E11-24
pubmed: 21540450
JCI Insight. 2017 Jun 2;2(11):null
pubmed: 28570274
Blood. 2003 Jan 15;101(2):729-38
pubmed: 12393603
J Am Acad Dermatol. 2017 Mar;76(3):377-390
pubmed: 28212759
F1000Res. 2015 May 28;4(F1000 Faculty Rev):132
pubmed: 27006754
Cell Death Dis. 2018 May 22;9(6):588
pubmed: 29789551
J Clin Invest. 2007 Jun;117(6):1605-15
pubmed: 17492054
Clin Rheumatol. 2017 Aug;36(8):1765-1772
pubmed: 28601944
Lancet. 2015 Sep 5;386(9997):983-94
pubmed: 26025581
Cell Mol Life Sci. 2013 Jun;70(12):2205-20
pubmed: 23334186
Nat Med. 2005 Jan;11(1):43-9
pubmed: 15592573
J Invest Dermatol. 2013 Feb;133(2):361-70
pubmed: 22951731
Nat Rev Rheumatol. 2010 Dec;6(12):704-14
pubmed: 20877306
Sex Dev. 2012;6(4):169-77
pubmed: 22571926
Cell Rep. 2014 Apr 24;7(2):464-475
pubmed: 24703841
J Clin Invest. 2017 Apr 3;127(4):1136-1145
pubmed: 28319043
Endocrinology. 2013 Mar;154(3):993-1007
pubmed: 23384835
Adv Exp Med Biol. 2015;872:3-31
pubmed: 26215988
Front Pharmacol. 2014 Jul 17;5:169
pubmed: 25100999
Arthritis Rheum. 2013 May;65(5):1203-12
pubmed: 23335223
Endocrinology. 2008 Mar;149(3):1377-88
pubmed: 18039792
Clin Exp Allergy. 2009 May;39(5):647-54
pubmed: 19260870
Trends Pharmacol Sci. 2013 Sep;34(9):518-30
pubmed: 23953592
Nature. 2005 Sep 15;437(7057):369-75
pubmed: 16163348
J Invest Dermatol. 2017 Aug;137(8):1609-1611
pubmed: 28735612
Int J Mol Sci. 2017 Nov 16;18(11):null
pubmed: 29144382
Front Immunol. 2018 May 30;9:1210
pubmed: 29899748
FASEB J. 2014 Dec;28(12):5055-70
pubmed: 25205742
Immunity. 1997 Dec;7(6):803-12
pubmed: 9430225
Biochem Biophys Res Commun. 2006 Dec 8;351(1):266-72
pubmed: 17054908
Oncotarget. 2015 Nov 17;6(36):38446-57
pubmed: 26498359
J Biol Chem. 2010 Apr 2;285(14):10385-96
pubmed: 20124407
J Leukoc Biol. 2019 Jan;105(1):187-194
pubmed: 30371949
Nature. 2002 Jun 20;417(6891):861-6
pubmed: 12075355
Arthritis Rheum. 2010 Sep;62(9):2651-61
pubmed: 20496421
Exp Dermatol. 2014 Jun;23(6):369-374
pubmed: 24888781
Int J Mol Sci. 2017 Oct 20;18(10):null
pubmed: 29053578
Nature. 2013 Apr 25;496(7446):461-8
pubmed: 23467089
Cell Rep. 2014 May 22;7(4):938-9
pubmed: 24856295
J Immunol. 2015 Jun 15;194(12):6057-67
pubmed: 25964494
J Invest Dermatol. 2012 Nov;132(11):2552-64
pubmed: 22763790
Blood. 2006 Feb 1;107(3):1039-47
pubmed: 16204313
J Invest Dermatol. 2015 Jun;135(6):1638-1648
pubmed: 25317845
J Invest Dermatol. 2007 Jun;127(6):1292-308
pubmed: 17429444
J Immunol. 2015 May 15;194(10):4940-50
pubmed: 25876761
Exp Ther Med. 2015 Aug;10(2):419-422
pubmed: 26622331
Sci Rep. 2016 Dec 09;6:38825
pubmed: 27934944
J Autoimmun. 2015 Jul;61:73-80
pubmed: 26077873
J Biol Chem. 2007 Dec 14;282(50):36303-13
pubmed: 17956870
Int J Mol Sci. 2018 Jun 29;19(7):null
pubmed: 29966221
Int J Endocrinol. 2012;2012:561018
pubmed: 23213332
Front Endocrinol (Lausanne). 2018 May 16;9:235
pubmed: 29867767
Atherosclerosis. 2014 Jun;234(2):391-400
pubmed: 24747114
F1000Prime Rep. 2014 Jan 02;6:4
pubmed: 24592316
J Invest Dermatol. 2017 Jul;137(7):1474-1483
pubmed: 28259685
Ann Rheum Dis. 2016 Apr;75(4):739-47
pubmed: 26612340
Neurotherapeutics. 2012 Jan;9(1):210-25
pubmed: 22125095
J Dtsch Dermatol Ges. 2015 Nov;13(11):1119-23
pubmed: 26513068
Clin Rev Allergy Immunol. 2018 Dec;55(3):295-311
pubmed: 28780731
Front Immunol. 2018 Jun 04;9:1232
pubmed: 29915587
EMBO Mol Med. 2013 Mar;5(3):456-70
pubmed: 23495141
J Allergy Clin Immunol. 2007 Jan;119(1):115-22
pubmed: 17208592
Shock. 2019 Aug;52(2):208-214
pubmed: 30124596
EMBO J. 2004 Apr 21;23(8):1770-81
pubmed: 15057277
J Biol Chem. 2011 Dec 30;286(52):44799-810
pubmed: 21965677
Kidney Int. 2017 May;91(5):1159-1177
pubmed: 28094030
Blood. 2015 Oct 8;126(15):1790-801
pubmed: 26276664
J Immunol. 2009 May 1;182(9):5836-45
pubmed: 19380832
Pharmacol Rev. 2016 Jan;68(1):49-75
pubmed: 26668301

Auteurs

Lisa M Sevilla (LM)

Animal Models of Skin Pathologies Unit, Instituto de Biomedicina de Valencia (IBV)-CSIC, Valencia, Spain.

Paloma Pérez (P)

Animal Models of Skin Pathologies Unit, Instituto de Biomedicina de Valencia (IBV)-CSIC, Valencia, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH